ISIS-APO(a)Rx + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Lipoprotein(a)
Conditions
Elevated Lipoprotein(a)
Trial Timeline
Jun 1, 2014 → Nov 1, 2015
NCT ID
NCT02160899About ISIS-APO(a)Rx + Placebo
ISIS-APO(a)Rx + Placebo is a phase 2 stage product being developed by Ionis Pharmaceuticals for Elevated Lipoprotein(a). The current trial status is completed. This product is registered under clinical trial identifier NCT02160899. Target conditions include Elevated Lipoprotein(a).
What happened to similar drugs?
0 of 4 similar drugs in Elevated Lipoprotein(a) were approved
Approved (0) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02160899 | Phase 2 | Completed |
Competing Products
12 competing products in Elevated Lipoprotein(a)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 47 |
| Baricitinib | Eli Lilly | Pre-clinical | 26 |
| Rosuvastatin | AstraZeneca | Phase 3 | 32 |
| TQJ230 + Placebo | Novartis | Phase 3 | 44 |
| LIK066 + Placebo | Novartis | Phase 2 | 35 |
| Olpasiran | Amgen | Phase 1 | 29 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 42 |
| Ivabradine | Amgen | Phase 3 | 32 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 26 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 26 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 32 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 26 |